Large-Scale Docking in the Cloud
- PMID: 37071086
- PMCID: PMC10170500
- DOI: 10.1021/acs.jcim.3c00031
Large-Scale Docking in the Cloud
Abstract
Molecular docking is a pragmatic approach to exploit protein structures for new ligand discovery, but the growing size of available chemical space is increasingly challenging to screen on in-house computer clusters. We have therefore developed AWS-DOCK, a protocol for running UCSF DOCK in the AWS cloud. Our approach leverages the low cost and scalability of cloud resources combined with a low-molecule-cost docking engine to screen billions of molecules efficiently. We benchmarked our system by screening 50 million HAC 22 molecules against the DRD4 receptor with an average CPU time of around 1 s per molecule. We saw up to 3-fold variations in cost between AWS availability zones. Docking 4.5 billion lead-like molecules, a 7 week calculation on our 1000-core lab cluster, runs in about a week depending on accessible CPUs, in AWS for around $25,000, less than the cost of two new nodes. The cloud docking protocol is described in easy-to-follow steps and may be sufficiently general to be used for other docking programs. All the tools to enable AWS-DOCK are available free to everyone, while DOCK 3.8 is free for academic research.
Conflict of interest statement
The authors declare the following competing financial interest(s): J.J.I. is a co-founder of Blue Dolphin Lead Discovery LLC, a contract research organization for molecular docking screens. He is also a co-founder of Deep Apple Therapeutics, Inc.
Figures
References
-
- Lyu J.; Wang S.; Balius T. E.; Singh I.; Levit A.; Moroz Y. S.; O’Meara M. J.; Che T.; Algaa E.; Tolmachova K.; Tolmachev A. A.; Shoichet B. K.; Roth B. L.; Irwin J. J. Ultra-Large Library Docking for Discovering New Chemotypes. Nature 2019, 566, 224–229. 10.1038/s41586-019-0917-9. - DOI - PMC - PubMed
-
- Stein R. M.; Kang H. J.; McCorvy J. D.; Glatfelter G. C.; Jones A. J.; Che T.; Slocum S.; Huang X. P.; Savych O.; Moroz Y. S.; Stauch B.; Johansson L. C.; Cherezov V.; Kenakin T.; Irwin J. J.; Shoichet B. K.; Roth B. L.; Dubocovich M. L. Virtual Discovery of Melatonin Receptor Ligands to Modulate Circadian Rhythms. Nature 2020, 579, 609–614. 10.1038/s41586-020-2027-0. - DOI - PMC - PubMed
-
- Gorgulla C.; Boeszoermenyi A.; Wang Z. F.; Fischer P. D.; Coote P. W.; Padmanabha Das K. M.; Malets Y. S.; Radchenko D. S.; Moroz Y. S.; Scott D. A.; Fackeldey K.; Hoffmann M.; Iavniuk I.; Wagner G.; Arthanari H. An Open-Source Drug Discovery Platform Enables Ultra-Large Virtual Screens. Nature 2020, 580, 663–668. 10.1038/s41586-020-2117-z. - DOI - PMC - PubMed
-
- Sadybekov A. A.; Brouillette R. L.; Marin E.; Sadybekov A. V.; Luginina A.; Gusach A.; Mishin A.; Besserer-Offroy E.; Longpre J. M.; Borshchevskiy V.; Cherezov V.; Sarret P.; Katritch V. Structure-Based Virtual Screening of Ultra-Large Library Yields Potent Antagonists for a Lipid Gpcr. Biomolecules 2020, 10, 1634. 10.3390/biom10121634. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
